tadalafil has been researched along with vardenafil in 13 studies
Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (vardenafil) | Trials (vardenafil) | Recent Studies (post-2010) (vardenafil) |
---|---|---|---|---|---|
1,742 | 392 | 1,089 | 32 | 0 | 20 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (46.15) | 29.6817 |
2010's | 7 (53.85) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Adam, L; Beyer, B; Chong, S; Ferrer, P; He, B; Henwood, A; Humphrey, WG; Krupinski, J; Macor, JE; Mason, H; Normandin, D; Pongrac, R; Seliger, L; Wang, J; Wu, X; Yu, G; Zhang, R | 1 |
Artis, DR; Bollag, G; Card, GL; England, BP; Fong, D; Gillette, S; Ibrahim, PN; Kim, SH; Lee, B; Luu, C; Milburn, MV; Powell, B; Schlessinger, J; Suzuki, Y; Tabrizizad, M; Zhang, KY | 1 |
Asberom, T; Boyle, CD; Chackalamannil, S; Chintala, M; Clader, JW; Greenlee, WJ; Guzik, H; Hu, Y; Hu, Z; Kurowski, S; Lankin, CM; Myers, J; Palamanda, J; Pissarnitski, DA; Skell, J; Stamford, AW; Vemulapalli, S; Wang, P; Wang, Y; Wu, P; Xu, R | 1 |
Hughes, RA; Manallack, DT; Thompson, PE | 1 |
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Antunes, JE; da Cunha, EF; Freitas, MP; Ramalho, TC; Rittner, R | 1 |
Arancio, O; Deng, SX; Feng, Y; Fiorito, J; Francis, YI; Landry, DW; Rao, S; Saeed, F; Staniszewski, A; Thakkar, DM; Zhang, H | 1 |
Fujishige, K; Hikota, M; Kikkawa, K; Koga, Y; Kotera, J; Matsuki, K; Morimoto, H; Murakami, M; Omori, K; Sakamoto, T; Yamada, K | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Cuadrado-Tejedor, M; de Miguel, I; Espelosin, M; Estella-Hermoso de Mendoza, A; García-Barroso, C; Garcia-Osta, A; Haizhong, T; Musheng, X; Oyarzabal, J; Pérez-González, M; Rabal, O; Sáez, E; Sánchez-Arias, JA; Ugarte, A; Ursua, S; Wei, W | 2 |
Leeson, PD; Young, RJ | 1 |
Cheng, C; Jiang, Y; Lou, H; Qiao, Y; Sun, B; Tan, J; Wu, Y; Xie, Z; Zhao, S; Zheng, H | 1 |
3 review(s) available for tadalafil and vardenafil
Article | Year |
---|---|
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Cyclic AMP; Cyclic GMP; Drug Design; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Quantitative Structure-Activity Relationship; Xanthines | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.
Topics: Animals; Chemical Phenomena; Drug Discovery; Humans; Hydrophobic and Hydrophilic Interactions | 2018 |
10 other study(ies) available for tadalafil and vardenafil
Article | Year |
---|---|
Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Administration, Oral; Animals; Biological Availability; Blood Pressure; Cyclic Nucleotide Phosphodiesterases, Type 5; Dogs; Enzyme Inhibitors; Erectile Dysfunction; Female; Male; Penis; Pyridazines; Rabbits; Rats; Structure-Activity Relationship | 2003 |
Structural basis for the activity of drugs that inhibit phosphodiesterases.
Topics: Binding Sites; Crystallography, X-Ray; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Structure, Tertiary | 2004 |
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Male; Models, Molecular; Molecular Structure; Phosphodiesterase I; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Rats; Sildenafil Citrate; Structure-Activity Relationship; Sulfones; Vasodilator Agents | 2005 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil.
Topics: Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Imidazoles; Mice; Models, Molecular; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Quantitative Structure-Activity Relationship; Rats; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2008 |
Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Drug Discovery; Female; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Phosphodiesterase 5 Inhibitors; Quinolines | 2013 |
The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.
Topics: Animals; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Pyrimidines; Rabbits | 2014 |
Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
Topics: Acetylation; Alzheimer Disease; Animals; Cell Line; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Models, Molecular; Phosphodiesterase 5 Inhibitors | 2016 |
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Design; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Molecular Structure; Neuroglia; Phosphodiesterase 5 Inhibitors; Structure-Activity Relationship | 2018 |
Discovery of furyl/thienyl β-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect.
Topics: Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Female; Humans; Male; Mesenteric Arteries; Molecular Docking Simulation; Phosphodiesterase 5 Inhibitors; Rats, Wistar; Structure-Activity Relationship; Vasodilator Agents | 2018 |